Modification by analgesics of lesion development in the urinary tract and various other organs of rats pretreated with dihydroxy-di-N-propylnitrosamine and uracil.
Effects of the analgesics phenacetin, acetaminophen and antipyrine on lesion development in the urinary tract and other organs in male F344 rats were investigated. Animals were concurrently administered with 0.1% dihydroxy-di-N-propylnitrosamine (DHPN) in drinking water and 3.0% uracil in the diet for 4 weeks and then, starting 1 week after the cessation of this treatment, received basal diet or diet containing phenacetin, acetaminophen or antipyrine for 35 weeks. The occurrences of renal cell tumors were increased in the groups given phenacetin or antipyrine, as compared with the DHPN + uracil alone controls. Antipyrine, but not the two other compounds, also enhanced development of hyperplastic lesions in the renal pelvis and ureter. In the urinary bladder, phenacetin and antipyrine treatments were both associated with increased incidence of preneoplastic or neoplastic lesions. Furthermore, phenacetin alone, without the initiating agent pretreatments, induced simple hyperplasias of the urinary bladder at high incidence. Antipyrine enhanced induction of hyperplastic lesions in the ureter and was also found to increase the incidences of preneoplastic and neoplastic lesions in the liver. Although decreased incidences of tumor development of lung and thyroid were observed for the group given phenacetin, this might have been linked to the decreased weight gain. The results confirmed that combination treatment with DHPN + uracil is effective for wide-spectrum initiation of carcinogenesis in the urological tract and demonstrated significant modification potential for both phenacetin and antipyrine.
Shibata
M A
MA
First Department of Pathology, Nagoya City University Medical School.
Sano
M
M
Hagiwara
A
A
Hasegawa
R
R
Shirai
T
T
D000082:Acetaminophen / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000983:Antipyrine / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced; D008297:Male; D009153:Mutagens / Q000494:pharmacology*; D009602:Nitrosamines / Q000494:pharmacology*; D010615:Phenacetin / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D014498:Uracil / Q000494:pharmacology*; D014551:Urinary Tract / Q000187:drug effects / Q000473:pathology; D014571:Urologic Neoplasms / Q000139:chemically induced* / Q000473:pathology
D000700:Analgesics; D002273:Carcinogens; D009153:Mutagens; D009602:Nitrosamines; D000082:Acetaminophen; C012457:diisopropanolnitrosamine; D014498:Uracil; D010615:Phenacetin; D000983:Antipyrine